October 8, 2015


Cipla inks pact with Biopharma SPA to establish joint venture in Algeria

Drug major Cipla has inked a pact with Biopharma SPA for establishing a joint venture company in Algeria to manufacture and market respiratory products.

“Cipla (EU) Ltd, a wholly-owned subsidiary of the company has entered into a definitive agreement with Biopharma SPA for establishing a joint venture company in Algeria,” Cipla said in a regulatory filing.


Continue Reading >

October 8, 2015


Delayed IPF Diagnosis Negatively Impacts Patients by Delaying Treatment According to Global Survey of Pulmonologists1

  • Nearly 9 out of 10 pulmonologists surveyed believe a delay in IPF diagnosis negatively impacts patients
  • Slowing disease progression is considered the priority when selecting a pharmaceutical treatment
  • Breathlessness and lung function are top of mind when pulmonologists think about the impact of IPF1

A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis (IPF) negatively impacts patients."...

Continue Reading >

October 7, 2015


FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

The EF-14 trial achieved statistically significant extension of both progression-free survival and overall survival in newly diagnosed glioblastoma with a 50% increase in the number of patients alive two-years after starting treatment when treated with TTFields in combination with temozolomide as compared to temozolomide alone

Novocure (NASDAQ: NVCR) announced today that"...

Continue Reading >

October 5, 2015


Replicor Announces Initiation of Recruitment for Its Phase IIb Clinical Trial with REP 2139-Mg or REP 2165-Mg in Combination with Viread® and Pegasys® or Zadaxin® in Patients with HBeAg Negative Chronic Hepatitis B Infection

Replicor announces that the recruitment of patients is underway for its second Phase II trial in Caucasian patients that will assess the safety and antiviral efficacy of REP 2139-Mg or REP 2165-Mg in combination with Viread® and Pegasys® or Zadaxin® in patients with HBeAg negative chronic hepatitis B infection.

The design of the REP 401 protocol (NCT02565719)"...

Continue Reading >

October 4, 2015


Antidiabetic drugs produced in Tizi Ouzou to be exported abroad from 2016

The chief executive officer of Danish laboratories Novo Nordisk, Lars Rebien Sorens, has announced that antidiabetic drugs produced by the plant of Tizi Ouzou (103-km east of Algiers), as part of a partnership between Algeria and Denmark, will be exported abroad from 2016.

Lars, speaking with Minister of Health, Population and Hospital Reform Abdelmalek Boudiaf, stressed"...

Continue Reading >

October 4, 2015


Dr. Michael’s Dental Clinic in Opens Doors to New Dentist

Dr. Michael’s Dental Clinic, the leading and most advanced dental health care provider in the region, welcomes Dr. Ladan Sahirad to its team. She is an accomplished dentist with over 10 years of private practice in London, UK.

“Dentistry is a career that provides plenty of rewards and challenges as well as an opportunity to help people and make communities healthier"...

Continue Reading >

September 30, 2015


HOYA Group PENTAX Medical Announces Expansion into Endoscopic Therapy through Strategic Investment in Creo Medical Ltd.

HOYA Group PENTAX Medical has entered into an agreement to invest in Creo Medical Ltd., a leading electrosurgical energy devices company based in the U.K. The official documents formalizing the agreement were signed on September 10, 2015 — subject to regulatory approvals by the relevant authorities, PENTAX Medical has acquired an interest in Creo Medical Ltd. PENTAX Medical has identified endoscopic therapeutic devices as a priority area in its growth strategy, and equity participation in Creo Medical Ltd. accelerates"...

Continue Reading >

September 29, 2015


MCI to Organise Asia-Pacific Breast Cancer Summit in Singapore

MCI is proud to announce the fifth edition of the Asia Pacific Breast Cancer Summit (APBCS) will be held in Singapore from 27 – 28 February 2016. At the summit, educational leaders and delegates will come together and share their knowledge to further the research and development of breast cancer treatment.

With the support of the Singapore Exhibitions and Conventions"...

Continue Reading >

September 29, 2015



Diabetes is a metabolic disorder in which the body does not produce or properly use insulin, a hormone that allows the body to use blood sugar for energy. It is characterized by high levels of blood sugar, which can cause changes in the blood vessels of the retina, the light-sensitive tissue at the back of the eye that is necessary for good vision.


Continue Reading >

September 29, 2015


New data demonstrate sustained long-term efficacy of OFEV®* on slowing disease progression and safety in patients with IPF

  • Interim analysis of INPULSIS®-ON study shows: Beneficial effect of OFEV®* on slowing disease progression was maintained and the change from baseline in FVC was consistent over 2 years1
  • Long-term treatment with OFEV®* had a manageable safety and tolerability profile (mean exposure of 2.4 years, maximum exposure of more than 3 years)1
  • Commonly used concomitant medications, such as anti-acids or systemic steroids, do not influence the beneficial effect of OFEV®* on slowing disease progression2,3


Continue Reading >

Forex Market Video